Clinical Trials

Study Title:
A Phase 3, Open label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR mutated Advanced or Metastatic Non small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy

For more information about the trial above please contact the study team: Medical University of South Carolina Principal Investigator, Mariam Alexander, at alexanma@musc.edu. Study Coordinator, Jessica Shealor, at shealorj@musc.edu. Trial opened at the following institutions: Medical University of South Carolina